National Institute for Health and Care Excellence says 'yes' to Darzalex®▼ (daratumumab) for relapsed and refractory multiple myeloma

National Institute for Health and Care Excellence says ‘yes’ to Darzalex®▼ (daratumumab) for relapsed and refractory multiple myeloma High Wycombe, 15th March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson welcomes the decision by the National Institute for Health and...

Related Keywords

High Wycombe ,Buckinghamshire ,United Kingdom ,Amanda Cunnington ,National Institute For Health ,Cancer Drugs Fund ,Janssen Pharmaceutical Companies Of Johnson ,National Institute ,Care Excellence ,Janssen Pharmaceutical Companies ,Final Appraisal Document ,Systemic Anti Cancer Therapy ,Patient Access ,Janssen Cilag Limited ,